文献速递睡眠呼吸障碍

乙酰唑胺联合阿托西汀治疗肥胖低通气综合征

Acetazolamide Plus Atomoxetine for Obesity Hypoventilation Syndrome Treatment.
PubMed 文献 · Chest · 2025-09-25

这项随机双盲交叉试验在15例未接受PAP治疗的肥胖低通气综合征患者中,比较2周乙酰唑胺500mg联合阿托西汀100mg每日与安慰剂的疗效。结果显示联合治疗显著降低夜间平均二氧化碳分压和日间二氧化碳,并改善AHI和血氧,无严重不良事件。

要点

  • 乙酰唑胺联合阿托西汀可显著降低OHS患者夜间Ptcco2和日间CO2。
  • 联合治疗还降低AHI并提高夜间SpO2,且未发生严重不良事件。
  • 结果为OHS的潜在药物治疗提供了概念验证证据。

核心结论

  • 乙酰唑胺联合阿托西汀可显著改善未接受PAP治疗的OHS患者的睡眠相关低通气、氧合参数和AHI。

研究设计与样本

  • 随机、双盲、交叉试验,比较2周乙酰唑胺500mg联合阿托西汀100mg每日与安慰剂。
  • 纳入15例未接受PAP治疗、BMI≥35 kg/m2的OHS患者。

主要发现

  • 联合治疗较安慰剂使夜间Ptcco2平均降低5.8 mm Hg(95%CI -7.8至-3.7 mm Hg;P<.001)。
  • 联合治疗较安慰剂使日间CO2降低。
  • 中位AHI降低20.9事件/h(95%CI -26.7至-15.1事件/h;P<.001)。
  • 平均整夜SpO2提高4.3%(95%CI 2.8%至5.7%;P<.001)。
  • 未发生严重不良事件。

临床怎么用

  • 该联合方案可能为未接受PAP治疗的OHS患者提供药物选择,但需进一步验证。

局限性

  • 样本量小(15例),为概念验证研究。
  • 治疗时长仅2周,长期疗效与安全性未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A subgroup of patients with obesity exhibits hypoventilation as a result of, among other mechanisms, a narrow, collapsible upper airway (UA), a reduced ventilatory drive during both wakefulness and sleep, and the loss of pharyngeal muscle tone during sleep. These features characterize obesity-hypoventilation syndrome (OHS). If left untreated, OHS is associated with significant morbidity and mortality. Besides lifestyle modifications, positive airway pressure (PAP) is the only available treatment, and it is often not well tolerated. Drugs designed to activate UA muscles such as atomoxetine and to stimulate breathing such as acetazolamide represent a potential novel strategy for treating OHS. RESEARCH QUESTION: Is 2 weeks of 500 mg acetazolamide plus 100 mg atomoxetine daily effective for OHS severity (reduction in mean nocturnal CO2 as the primary outcome)? STUDY DESIGN AND METHODS: In a randomized, double-masked crossover trial, we compared 2 weeks of acetazolamide plus atomoxetine with placebo in patients with OHS not treated with PAP. Patients with a BMI of ≥ 35 kg/m2 underwent polysomnography with transcutaneous overnight measurement of CO2 (Ptcco2) and morning blood test to evaluate sleep-related and diurnal hypercapnia at baseline and after each treatment sequence. RESULTS: Fifteen patients with a median age of 53 years (interquartile range [IQR], 36-59 years; 8 female patients; median BMI, 44 kg/m2 [IQR, 42-53 kg/m2]; baseline median Ptcco2, 49 mm Hg [IQR, 44-55 mm Hg]; median apnea-hypopnea index (AHI), 64 events/h [IQR, 36-83 events/h], and median nocturnal peripheral capillary oxygen saturation (Spo2), 84% [IQR, 79%-89%]) were randomized. Acetazolamide plus atomoxetine decreased nocturnal Ptcco2 by a mean of -5.8 mm Hg (95% CI, -7.8 to -3.7 mm Hg; P < .001) and diurnal CO2 compared with placebo. Median AHI decreased by -20.9 events/h (95% CI, -26.7 to -15.1 events/h; P < .001) and mean overnight Spo2 increased by 4.3% (95% CI, 2.8%-5.7%; P < .001). No serious adverse events occurred. INTERPRETATION: Our results show that the administration of acetazolamide plus atomoxetine significantly improved sleep-related hypoventilation, oxygen parameters, and AHI in treatment-naive patients with OHS. This proof-of-concept study provides encouraging results for a potential pharmacotherapy for OHS. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT05448443; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Perger E, Parati G, Faini A, et al. Acetazolamide Plus Atomoxetine for Obesity Hypoventilation Syndrome Treatment. Chest. 2025. PMID: 41015199. doi:10.1016/j.chest.2025.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。